Worldwide, it is now well known that molecular markers, especially EGFR activating mutations, identify a subset of patients with NSCLC whose outcome is better with tyrosine kinase EGFR targeted therapies [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.